Dipeptidyl peptidase IV inhibitors and their uses as...

Details Dipeptidyl peptidase IV inhibitors and their uses as... Dipeptidyl peptidase IV inhibitors and their uses as...

2008-05-06

2008-05-06

Kosar, Andrew D. (Department: 1654)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S530000

Reexamination Certificate

active

11481349

ABSTRACT:
The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne et al.
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5827898 (1998-10-01), Khandwals et al.
patent: 5877202 (1999-03-01), Bitonti et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Vollhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6517824 (2003-02-01), Kohn et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 6605589 (2003-08-01), Uckun et al.
patent: 7109347 (2006-09-01), von Hoersten et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-10-01), None
patent: 198 26 972 (1999-12-01), None
patent: 198 34 610 (2000-02-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 1 130 022 (2001-09-01), None
patent: 2085665 (1971-12-01), None
patent: 2696740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 04-334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/01812 (1993-02-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/20061 (1993-10-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/22327 (1995-08-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/41220 (1999-08-01), None
patent: WO 99/41224 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 00/53596 (2000-09-01), None
patent: WO 00/58360 (2000-10-01), None
patent: WO 01/09169 (2001-02-01), None
patent: WO 01/32624 (2001-05-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/94310 (2001-12-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/13821 (2002-02-01), None
patent: WO 02/20825 (2002-03-01), None
patent: WO 03/016335 (2003-02-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 04/089366 (2004-10-01), None
Amasheh, et al.; “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus laevisoocytes”;Journal of Physiology; (1997); 504(1): 169-174.
Ansorge, et al.; “Membrane-bound peptidases of lymphocytes; Functional implications”;Biomed. Biochim. Acta; (1991); 50(4-6); 799-807.
Arai, et al. “Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships: In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain”;Chem. Pharm. Bull.; (1993); 41(i): 1583-1588.
Ashworth, et al.; “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”;Bioorganic&Medicinol Chemistry Letters; (1996); 6(10): 1163-1166.
Augustyns, et al.; “Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV”;Eur. J. Ed. Chem.; (1997); 32: 301-309.
Badia-Elder, et al; “Effects of Neuropeptide (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (Hadi/Ladi) rats”;Purdue School of Science; (2000).
Bergmeier; “The Synthesis of Vicinal Amino Alcohols”;Tetrahedron; (2000); 56: 2561-2576.
Welch, et al.; “Medical Management of Non-Insulin-Dependent (Type II) Diabetes”;ADA—Third Edition; (1994); 3-4.
Campbell, et al.; “Sulphonylureas and metformin: efficacy and inadequacy”;New Antidiabetic Drugs; (1990); 33-51.
Chemical Abstract 115;1-Pharmacology; (1991); 115: 37.
Chemical Abstract 118;34-Amino Acids, Peptides, Proteins; (1993); 118: 933.
Chemical Abstract 126;7-Enzymes; (1997); 126(2): 241.
Deacon, et al.; “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I are Rapidly Degraded from the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects”;Diabetes; (1995); 4: 1126-1131.
Deacon, et al.; “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo”;J. of Clinical Endocrinology and Metabolism; (1996); 80: 952-957.
Dodge, et al.; “Folding and Unfolding Kinetics of the Proline-to-Alanine Mutants of Bovine Pancreatic Ribonuclease A′”;Biochemistry; (1996); 35: 1548-1559.
Duncan; “Diseases of Metabolism: Detailed Methods of Diagnosis and Treatment”; (1964); 951-957.
Durinx, et al.; “Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters”;Clin. Chem. Lab. Med.; (2001); 39(2): 155-159.
Edwards, et al.; “Synthesis and activity of NH2- and COOH-terminal elastase recognition sequences on cotton”;J. Peptide Res.; (1999); 54: 536-543.
Endroczi, et al.; “Dipeptidyl Peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and ZN2=In Vitro”;Acta Physiologica Hungarian(1996); 75(1): 35-44.
Frohman, et al.; “Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma In Vitro and In Vivo to a biologically Inactive Product Cleaved at the NH2Terminus”;J. Clin. Invest.; (1986); 78: 906-913.
Gomez, et al.; “Relationship between endo- and expopetidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase”;Proc. Natl. Acad. Sci. USA; (1988); 85: 5468-5472.
Goodman & Gilman's; “Hormone and Hormone Antagonists”;The Pharmacological Basis of Therapeutics Ninth Edition; (1996); 1510.
Gossrau; “Cytochemistry of membrane proteases”;Histochem J.; (1985) 17(7): 737-71
Gutniak, et al.; “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”;New England J. Med.; (1992); 326: 1316-1322.
Gutniak, et al.; “Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM”;Diabetes Care; (1994); 17(9): 1039-1044.
Hahn, et al.; “Enzyme histochemical evidence for the presence of potential blood pressure regulating proteases in cultured villous explants from human first trimester placentae”;Acta

Affiliated with

Also associated with

Rating

Dipeptidyl peptidase IV inhibitors and their uses as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dipeptidyl peptidase IV inhibitors and their uses as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptidyl peptidase IV inhibitors and their uses as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3907703